Table 1 Basic characteristics and quality rating of the included studies
Study, year | Context country | Study design | Study population total/N | Female IBM n/% | Applied diagnostic criteria IBM n | Risk of bias assessment | ||
|---|---|---|---|---|---|---|---|---|
NOS | AXIS | MMAT | ||||||
Feldon et al. [34], 2017 | USA, Canada | Cross-sectional | IIM 1648/ PM 481 DM 702 IBM 465 | 186/40 | n not stated; possible or probable IBM [40];* | 7/9 | Yes: 11 No: 5 Do not know: 4 | Yes: 5 No: 0 Can’t tell: 0 |
Goyal et al. [36], 2016 | USA | Cross-sectional | IBM 25 | 6/24 | 19 clinically defined IBM, 6 probable IBM [42] | 5/9 | Yes: 12 No: 3 Do not know: 5 | Yes: 2 No: 1 Can’t tell: 2 |
Rose et al. [39], 2012 | USA | Cross-sectional | NMD 302/ LGMD 91 FSHD 49 PM/DM 19 IBM 24 MD 79 Misc 40 | 6/25 | > 6 months with confirmed diagnosis** | 7/9 | Yes: 14 No: 2 Do not know: 4 | Yes: 4 No: 0 Can’t tell: 1 |
Sadjadi et al. [38], 2010 | UK | Cross-sectional (RCT data) | IBM 60 | 22/37 | n not stated; definite or possible IBM [40] | 6/9 | Yes: 8 No: 4 Do not know: 8 | Yes: 4 No: 0 Can’t tell: 1 |
Gibson et al. [35], 2016 | USA | Qualitative | IBM 10 | 4/40 | 10 clinicopathologically defined IBM [42] | – | – | Yes: 5 No: 0 Can’t tell: 0 |
Ortega et al. [37], 2010 | Australia | Qualitative | IIM 14/ PM 8 DM 4 IBM 2 | not stated | n not stated; applied criteria [41] “South Australian Database for Patients With Biopsy-Proven Inflammatory Myositis” | – | – | Yes: 1 No: 1 Can’t tell: 3 |